Related Experiment Video
Updated: Jul 20, 2026

08:42
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
Quantitative evaluation of bile diversion surgery utilizing 99mTc HIDA scintigraphy
Gastroenterology
|February 1, 1983
Summary
Billroth II gastrectomy can cause significant enterogastric reflux. Diversion surgery effectively reduces reflux and improves symptoms like anemia and weight loss.
Area of Science:
- Gastroenterology
- Nuclear Medicine
- Surgical Oncology
Background:
- Billroth II gastrectomy is a common procedure for peptic ulcer disease.
- Post-gastrectomy complications include enterogastric reflux, leading to symptoms like epigastric pain and bleeding.
- Evaluating enterogastric reflux is crucial for patient management.
Observation:
- 21 patients with post-Billroth II gastrectomy symptoms were studied.
- 18 of 21 patients exhibited high enterogastric reflux indices (60%-95%) via 99mTc HIDA scintigraphy.
- Asymptomatic controls showed lower reflux indices (4%-45%).
Findings:
- Diversion antireflux surgery (Roux-en-Y or Henley loop) significantly reduced enterogastric reflux indices (2%-26%, p < 0.00001).
- Surgical intervention led to marked symptom improvement, including anemia correction and weight gain.
- 99mTc HIDA scintigraphy effectively quantifies reflux reduction post-surgery.
Implications:
- 99mTc HIDA scintigraphy is a valuable tool for assessing enterogastric reflux before and after surgical intervention.
- Antireflux surgery offers a viable solution for managing symptomatic enterogastric reflux after Billroth II gastrectomy.
- This study highlights the efficacy of surgical management in improving quality of life for affected patients.
More Related Videos
07:44Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
Published on: March 25, 2022
05:22Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
Published on: February 13, 2026